Equities

Arecor Therapeutics PLC

AREC:LSE

Arecor Therapeutics PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)77.50
  • Today's Change0.00 / 0.00%
  • Shares traded5.95k
  • 1 Year change42.20%
  • Beta0.4556
Data delayed at least 20 minutes, as of Feb 06 2026 10:41 GMT.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Arecor Therapeutics PLC had net income fall 19.66% from a loss of 8.55m to a larger loss of 10.24m despite a 10.50% increase in revenues from 4.57m to 5.05m.
Gross margin-2.45%
Net profit margin-160.13%
Operating margin-166.45%
Return on assets-103.79%
Return on equity-204.29%
Return on investment-187.88%
More ▼

Cash flow in GBPView more

In 2024, cash reserves at Arecor Therapeutics PLC fell by 1.85m. Cash Flow from Financing totalled 5.65m or 111.78% of revenues. In addition the company used 9.16m for operations while cash from investing totalled 1.72m.
Cash flow per share-0.21
Price/Cash flow per share--
Book value per share0.0756
Tangible book value per share0.075
More ▼

Balance sheet in GBPView more

Arecor Therapeutics PLC has a Debt to Total Capital ratio of 5.71%, a higher figure than the previous year's 3.33%.
Current ratio2.05
Quick ratio2.00
Total debt/total equity0.0606
Total debt/total capital0.0571
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.